HCPCS Q-Codes
Miscellaneous Services (Temporary Codes)

CMS assigns Q codes to procedures, services, and supplies on a temporary basis. When a permanent code is assigned, the Q code is deleted and cross-referenced.


View All HCPCS Sections
  • Q5134

    Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
  • Q5135

    Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
  • Q5136

    Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg
  • Q5137

    Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
  • Q5138

    Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg
  • Q5139

    Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
  • Q5140

    Injection, adalimumab-fkjp, biosimilar, 1 mg
  • Q5141

    Injection, adalimumab-aaty, biosimilar, 1 mg
  • Q5142

    Injection, adalimumab-ryvk biosimilar, 1 mg
  • Q5143

    Injection, adalimumab-adbm, biosimilar, 1 mg
  • Q5144

    Injection, adalimumab-aacf (idacio), biosimilar, 1 mg
  • Q5145

    Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg
  • Q5146

    Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg
  • Q5147

    Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg
  • Q5148

    Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
  • Q5149

    Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg
  • Q5150

    Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg
  • Q5151

    Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg
  • Q5152

    Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg
  • Q5153

    Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg
  • Q5154

    Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
  • Q5155

    Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
  • Q5156

    Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
  • Q5157

    Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
  • Q5158

    Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg
  • Q5159

    Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg
  • Q5160

    Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg
  • Q5161

    Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
  • Q5162

    Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
  • Q9001

    Assessment by chaplain services
  • Q9002

    Counseling, individual, by chaplain services
  • Q9003

    Counseling, group, by chaplain services
  • Q9004

    Department of veterans affairs whole health partner services
  • Q9950

    Injection, sulfur hexafluoride lipid microspheres, per ml
  • Q9951

    Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
  • Q9953

    Injection, iron-based magnetic resonance contrast agent, per ml
  • Q9954

    Oral magnetic resonance contrast agent, per 100 ml
  • Q9955

    Injection, perflexane lipid microspheres, per ml
  • Q9956

    Injection, octafluoropropane microspheres, per ml
  • Q9957

    Injection, perflutren lipid microspheres, per ml
  • Q9958

    High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml
  • Q9959

    High osmolar contrast material, 150-199 mg/ml iodine concentration, per ml
  • Q9960

    High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml
  • Q9961

    High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml
  • Q9962

    High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml
  • Q9963

    High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml
  • Q9964

    High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
  • Q9965

    Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml
  • Q9966

    Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml
  • Q9967

    Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/4/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.